Pharmaceutical formulations for acid labile substances
OwnerIsa Odidi, Amina Odidiinventors
Life of this patent
Estimating the term…
Abstract
This invention in general relates to novel pharmaceutical compositions for acid labile substances as well as for methods of making such. Specifically, the invention provides a pharmaceutical composition comprising about 1 to 75% by weight acid labile compound, up to about 5% by weight disintegrant, at least one protector coat layer used to separate and protect the acid labile substance from acid reacting groups and gastric juice, and at least one enteric coat layer which surrounds the protector coating layer and ensures delivery of over 80% the acid labile substance to the small intestine.
Claims15
A pharmaceutical composition comprising:
- about 1 to 75% by weight proton pump inhibitor compound;
- up to about 5% by weight disintegrant;
- at least one protector coat layer used to separate and protect the proton pump inhibitor compound from acid reacting groups and gastric juice, said protector coat layer comprising from about 0.1% to about 10% aminoalkyl methacrylate copolymers;
- and
- at least one enteric coat layer which surrounds the protector coating layer and ensures delivery of over 80% of the proton pump inhibitor compound to the small intestine.
A pharmaceutical composition comprising:
- about 1 to 75% by weight proton pump inhibitor compound selected from the group consisting of omeprazole and lansoprazole and their salts and mixtures thereof;
- up to about 5% by weight disintegrant;
- at least one protector coat layer used to separate and protect the proton pump inhibitor compound from acid reacting groups and gastric juice, said protector coat layer comprising compounds selected from the group consisting of aminoalkyl methacrylate copolymers and ethylcellulose;
- and
- at least one enteric coat layer which surrounds the protector coating layer and ensures delivery of over 80% of the proton pump inhibitor compound to the small intestine.
A pharmaceutical composition comprising:
- about 1 to 75% by weight proton pump inhibitor compound;
- up to about 5% by weight disintegrant;
- at least one protector coat layer used to separate and protect the proton pump inhibitor compound from acid reacting groups and gastric juice, wherein said protector coat layer comprises an aminoalkyl methacrylate copolymer;
- and
- at least one enteric coat layer which surrounds the protector coating layer and ensures delivery of over 80% of the proton pump inhibitor compound to the small intestine.
Dependencies are inferred from the claim text.